The report was prompted by the FDA's 2021 approval of the Alzheimer's disease drug aducanumab (Aduhelm) using the accelerated approval pathway. The aducanumab approval raised concerns in Congress ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback